Illinois Science + Technology Blog

May 2017

Fresenius Kabi will strengthen and diversify its product portfolio by acquiring Akorn and Merck KGaA's biosimilars business.  Stephan Sturm, CEO of Fresenius, said: "From a position of strength, Fresenius Kabi enhances and complements its business with two major steps. Akorn is an excellent strategic fit for Fresenius Kabi. The company's product portfolio is highly complementary to our well-developed generics business. The simultaneous entry into the biosimilars business is the right step into the right direction at the right time. The acquired biosimilars assets are an attractive opportunity for Fresenius Kabi to enter this strongly growing and highly profitable segment. Both acquisitions are milestones on Fresenius Kabi's growth path for this decade and beyond."

Akorn (formerly located at ISTP) produces and markets a diverse product portfolio of injectables, topical creams, ointments and gels, sterile ophthalmics, as well as oral liquids, otic solutions (for the ear), nasal sprays and respiratory drugs. Akorn products are sold in retail pharmacies (prescription and over-the-counter) and directly to physicians, in addition to hospitals and clinics - almost exclusively in the U.S. For the entire press release, click here.  
 

Past Postings

April 2017

Vetter- Partnership - Key to Success

Flexibility, responsiveness and operational excellence are... Read on >

February 2017

Chicago Startup Report

Chicago startups and tech companies raised more than $1.7 billion... Read on >

January 2016

Increased support of biotech research

Local biotech researchers should be in line for roughly $50... Read on >